Abcam, ab266343, Human RAD23A (hHR23A) knockout HEK-293T cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
RAD23A KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 2 bp deletion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 2 bp deletion in exon 2

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-RAD23A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The human homolog of Rad23A or hHR23A is an important player in protein maintenance and degradation pathways. This protein is known for its involvement in DNA repair mechanisms and proteasome function. hHR23A weighs approximately 43 kDa and expresses in many tissues reflecting its diverse roles throughout the body. Scientists also refer to it as RAD23A giving insight into its function by linking with the well-known RAD proteins.
Biological function summary
HHR23A contributes significantly to the protein ubiquitination process an essential cellular mechanism for targeting proteins for degradation. It forms part of a complex with ubiquitin aiding in the recognition and delivery of ubiquitinated proteins to the proteasome for degradation. The protein's ability to bind to both ubiquitin and the proteasome enables its dual function in proteolytic pathways positioning hHR23A as an intermediary that regulates protein turnover and stability.
Pathways
HHR23A engages in the ubiquitin-proteasome pathway and the nucleotide excision repair (NER) pathway. It cooperates with other proteins like Rad4 (XPC in humans) in NER where it functions in DNA damage recognition and repair. In the ubiquitin-proteasome pathway hHR23A interacts with the proteasomal subunit Rpn10 and other ubiquitin-like proteins. These interactions facilitate effective proteolysis of damaged or unnecessary proteins emphasizing its central role in controlling intracellular protein levels.
HHR23A has implications in neurodegenerative diseases and cancer. Impaired ubiquitin-proteasome system function involving hHR23A associates with neurodegenerative diseases such as Alzheimer's where protein aggregates accumulate. hHR23A's interaction with proteins like p53 known for its role in tumor suppression ties this protein to cancer biology highlighting its potential involvement in tumor suppression failure when its pathways are disrupted.